Novartis | NOVN - Ebitda


Novartis reported $4.77B in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Alcon AG USD 317M 337M Dec/2025
Almirall EUR 114.07M 60.37M Dec/2025
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.23B 272M Sep/2025
Autolus Therapeutics Ltd USD -70.08M 11.23M Sep/2025
Bayer EUR 1.97B 457M Dec/2025
Biogen USD 573.2M 253.7M Dec/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Fresenius EUR 850M 22M Sep/2025
Fresenius Medical Care EUR 1.07B 142.74M Dec/2025
Galapagos EUR 2.42M 161.13M Sep/2025
Genmab DKK 186M 291M Dec/2025
Gilead Sciences USD 4.03B 628M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
GRIFOLS EUR 347.24M 58.35M Jun/2025
Hikma Pharmaceutical USD 369M 84M Dec/2024
J&J USD 9.52B 389M Sep/2025
Lonza CHF 1.01B 54M Dec/2025
Merck EUR 1.44B 263M Dec/2025
Merck USD 8.39B 1.97B Sep/2025
Novartis USD 4.77B 1.11B Dec/2025
Novartis USD 5.84B 235M Sep/2025
Novo Nordisk DKK 37.3B 5.86B Dec/2025
Orion EUR 343M 207.9M Dec/2025
Pfizer USD 6.08B 351M Sep/2025
Philips EUR 738M 9M Sep/2025
Recordati EUR 247.15M 421K Dec/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 4.84B 2.95B Sep/2025
UCB EUR 1.6B 570M Dec/2025